Assembly Biosciences (ASMB) Amortization of Deferred Charges (2010 - 2011)
Assembly Biosciences' (ASMB) quarterly Amortization of Deferred Charges came in at $279933.0 in Q3 2011, down 70.01% year-on-year from $933412.0 in Q3 2010, and up 1306.06% quarter-over-quarter from $19909.0 in Q4 2010.
Assembly Biosciences (ASMB) Amortization of Deferred Charges (2010 - 2011) Analysis & Trends
Assembly Biosciences' Amortization of Deferred Charges history runs 2 years deep, the most recent figure standing at $279933.0 for Q3 2011.
- On a quarterly basis, Amortization of Deferred Charges fell 70.01% year-over-year to $279933.0 in Q3 2011; TTM through Jun 2012 was $279933.0, a N/A change from a year earlier, with the FY2011 full-year figure at $328958.0, down 85.86% from the prior year.
- Amortization of Deferred Charges climbed to $279933.0 in Q3 2011 per ASMB's latest filing, from $19909.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $933412.0 in Q3 2010 and bottomed at $19909.0 in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn |
| 10 | Assembly Biosciences | 442.87 Mn | 216.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2011 | 279,933.00 |
| Sep 30, 2011 | 279,933.00 |
| Dec 31, 2010 | 19,909.00 |
| Dec 31, 2010 | 19,909.00 |
| Sep 30, 2010 | 933,412.00 |
| Sep 30, 2010 | 933,412.00 |